Lightnews — Scholar-powered news

Chris Bahl

@cdbahl.com

1.2K followers 80 following 38 posts

protein geek, founder and CEO of AI Proteins @aiproteins.com https://linkedin.com/in/cdbahl

Posts Media Videos Starter Packs

Chris Bahl @cdbahl.com · Sep 3

We're looking for a mass spec expert to join our team at @aiproteins.com! This position is ideal for a freshly-minted PhD grad (or someone who will graduate within the next 6 months or less), or a rockstar scientist who earned their skills on the job in biotech

AI Proteins @aiproteins.com · Sep 3

We're #hiring a Scientist in Mass Spectrometry!

Apply today or share this post with your network: www.linkedin.com/jobs/view/42...
(ignore what linkedin says - the search is still open)

Interested? Please email your CV to: [email protected]

AI Proteins hiring Scientist in Mass Spectrometry Miniproteins and Bioconjugates in Greater Boston | LinkedIn

Posted 8:20:30 PM. The Company:AI Proteins is a Boston-based biotechnology company focused on the de novo design and…See this and similar jobs on LinkedIn.

www.linkedin.com

Reposted by Chris Bahl

Guilherme M. Arantes @garantes.bsky.social · Sep 1

🎥 Neste videocast produzido junto do @ieausp.bsky.social, tive uma conversa inspiradora com o Anderson Soares (UFG), @alexandre-cf.bsky.social e o @cdbahl.com sobre como a IA está moldando o futuro da biologia e da saúde humana. Assista aqui 👉 www.youtube.com/watch?v=qQbZ...

Inteligência Artificial Aplicada às Ciências da Vida

YouTube video by Instituto de Estudos Avançados da USP

www.youtube.com

Reposted by Chris Bahl

AI Proteins @aiproteins.com · Aug 26

Congratulations to Dr. James Bowman on his promotion to Chief Technology Officer!

www.businesswire.com/news/home/20...

www.businesswire.com

Chris Bahl @cdbahl.com · Aug 26

It’s a privilege to be building @aiproteins.com together with James and our unbelievably talented and dedicated team of people, all striving to make a difference in the world through our technology

www.businesswire.com/news/home/20...

www.businesswire.com

Chris Bahl @cdbahl.com · Aug 26

As our first CTO at @aiproteins.com, James will lead the continued acceleration of our platform capabilities in addition to the design, testing and optimization of many novel #miniprotein drug candidates

Chris Bahl @cdbahl.com · Aug 26

Our mission is to industrialize drug discovery to create programmable, #denovo protein-based medicines that help patients across a wide range of diseases

Chris Bahl @cdbahl.com · Aug 26

James has been one of the key architects of this vision since day one, and his insight and leadership these past ~4 years has shaped the discovery engine that powers @aiproteins.com today

Chris Bahl @cdbahl.com · Aug 26

What began as an idea — that we could scale de novo protein design — is now a fully-operational platform that integrates generative #AI with automated production and characterization in the wet lab

Chris Bahl @cdbahl.com · Aug 26

James joined my academic lab at the @ipiproteins.bsky.social in January of 2020 as a postdoc focused on #miniprotein de novo design and engineering. Less than 2 years later, James and I left academia together to found @aiproteins.com along with an incredible team of people from my former lab.

Chris Bahl @cdbahl.com · Aug 26

I am overjoyed to announce that James Bowman has been promoted to Chief Technology Officer at @aiproteins.com!

🧵👇

Chris Bahl @cdbahl.com · Jul 12

This was a lot of fun - thanks so much @yossefbaidi.bsky.social and @fang-xie.bsky.social ‪for the great conversation, and for your passion and excitement for biotech and entrepreneurship!

Yossef Baidi @yossefbaidi.bsky.social · Jun 20

During this episode, @fang-xie.bsky.social and I interview @cdbahl.com, co-founder and CEO of @aiproteins.com. We discuss with Chris his interest in protein science and how he started his academic lab at the @ipiproteins.bsky.social.

Reposted by Chris Bahl

Nick Polizzi @nickpolizzi.bsky.social · Apr 28

Super excited to share a new preprint from our lab on design of small-molecule binding proteins using neural networks! The paper has a bit of everything. A new graph neural network, new design algorithms, and experimental validation. www.biorxiv.org/content/10.1...
🧵🧪

Zero-shot design of drug-binding proteins via neural selection-expansion

Computational design of molecular recognition remains challenging despite advances in deep learning. The design of proteins that bind to small molecules has been particularly difficult because it requ...

www.biorxiv.org

Reposted by Chris Bahl

Institute for Protein Innovation @ipiproteins.bsky.social · May 1

#IPISeminar alert 🔔 Friday at 2 p.m. ET, Chris Bahl of AI Proteins will share the challenges of incorporating #artificialintelligence into #proteindesign & the impact reimagined #miniproteins can have on therapeutics. Join us through the QR code or follow the Zoom link on our calendar! rb.gy/xcee9l

Chris Bahl @cdbahl.com · Apr 15

And most importantly, a huge thank you to the phenomenal team at @aiproteins.bsky.social

Your dedication, ingenuity, and relentless pursuit of innovation are the driving force behind the amazing work we do. It's a privilege to lead such a talented group and to share our achievements with the world

Chris Bahl @cdbahl.com · Apr 15

I'm so grateful to Lily James Olds, Leonie Hoerster and Allegra Pearl from TED Conferences for providing such incredible support

Chris Bahl @cdbahl.com · Apr 15

It was an honor to speak from the main stage at TED last week about our work at AI Proteins

Our mission is to design the next generation of therapeutics built from de novo #miniproteins, and this was an unbelievable opportunity to help shape the broader conversation about the future of biologics

Chris Bahl @cdbahl.com · Feb 12

This is why I'm so excited to have Phil as our newest colleague - he's the best person on the planet to help us pave the way, and I know that we're going to create many amazing molecules together that improve the lives of patients everywhere.

Chris Bahl @cdbahl.com · Feb 12

Our de novo miniproteins are a novel modality, which means that we're writing the playbook for #miniprotein drug development as we go.

Chris Bahl @cdbahl.com · Feb 12

Big news to share! Phil Brandish has joined our team and will lead drug development efforts at AI Proteins. Phil is a rockstar, with a stellar track record and years of experience successfully bringing molecules into the clinic at Merck and Bicycle Therapeutics.

AI Proteins @aiproteins.com · Feb 12

Welcome Phil Brandish, Chief Development Officer, to the AI Proteins team!

www.businesswire.com/news/home/20...

AI Proteins Appoints Philip E. Brandish, PhD as Chief Development Officer

AI Proteins, Inc., a pioneering company utilizing artificial intelligence to design novel miniprotein therapeutics, today announced the appointment of

www.businesswire.com

Chris Bahl @cdbahl.com · Jan 25

go.bsky.app/53tEUeR

Chris Bahl @cdbahl.com · Jan 7

Wendy Dwyer, Mike Krepps and I will be in San Francisco next week for the J.P. Morgan Healthcare Conference, and we’d be delighted to chat - please feel free to reach out!

www.linkedin.com/in/wendy-dwy...
www.linkedin.com/in/michaeldk...

Chris Bahl @cdbahl.com · Jan 7

I am incredibly enthusiastic about the future of AI Proteins @aiproteins.bsky.social and the potential for our technology to create many transformative medicines. I am committed to building a world-class company that delivers significant value to patients, our partners, and investors.

Chris Bahl @cdbahl.com · Jan 7

We are prioritizing a key program in oncology (to be announced soon), and I believe this focused approach will maximize our chance of success. To ensure the company can withstand anything that comes our way, we are continuing to generate additional pipeline opportunities.

Chris Bahl @cdbahl.com · Jan 7

Second, we are committed to advancing our internal pipeline of assets towards clinical proof-of-concept. Achieving this milestone will be a major value inflection point for AI Proteins @aiproteins.bsky.social, demonstrating the power of our platform and validating our approach to drug discovery.

Chris Bahl @cdbahl.com · Jan 7

Momentum is building, and AI Proteins @aiproteins.bsky.social is ideally positioned to become the premier platform partner for the discovery and development of #denovo #miniprotein therapeutics